Skip to content
← All settings

DISEASE & TREATMENT SETTING

Stage IV Thyroid Cancer

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of Stage IV Papillary and Follicular Thyroid Cancer (Metastatic)

Broader topic: Thyroid Cancer

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
IV
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
      source wording
      Treatment of Stage IV Papillary and Follicular Thyroid Cancer (Metastatic)

      Study evidence for this setting

      7 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00410761 · Source cited / selected · Scope: unclear

      An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

      6 outcome links · 4 safety-group records · 1 quality-of-life measures

      →

      NCT00704730 · Source cited / selected · Scope: unclear

      Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT00896454 · Source cited / selected · Scope: unclear

      Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT02062632 · Registry condition search · Scope: unclear

      Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

      6 outcome links · 1 safety-group records · 3 quality-of-life measures

      →

      NCT04234113 · Registry condition search · Scope: unclear

      Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

      6 outcome links · 17 safety-group records · 0 quality-of-life measures

      →

      NCT04514484 · Registry condition search · Scope: unclear

      Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT04579757 · Registry condition search · Scope: unclear

      Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

      6 outcome links · 9 safety-group records · 0 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
        mappings

          Download this complete draft source relationship record →

          Preserved source evidence · Not medical advice